OralNausea and vomitingAdult: As hydrochloride: 50 mg up to tid, up to 200 mg/day. For prevention of motion sickness, 1st dose should be given 30 min before travelling.
Child: 6-12 yr: As hydrochloride: 25 mg up to tid. For prevention of motion sickness, 1st dose should be given 30 min before travelling.
ParenteralProphylaxis of postoperative nausea and vomitingAdult: As cyclizine lactate: 50 mg up to tid via slow IV inj over 20 minutes. May give 1st dose 20 minutes before anticipated end of surgery. Treatment should start within the the 1st 24 hours of surgery and should not continue beyond 48 hours.
|
Dose reductions may be needed.
|
Avoid in severe liver disease.
|
Cyclizine lactate may be incompatible with oxytetracycline hydrochloride, chlortetracycline hydrochloride, benzylpenicillin and solutions with a pH ≥6.8.
|
Premature or full-term neonates.
|
Angle closure glaucoma; urinary retention; prostatic hypertrophy; pyloroduodenal obstruction; epilepsy, severe CV disorders; known or suspected QT interval prolongation; hypokalaemia or other electrolyte imbalances; asthma; hepatic impairment. May impair ability to drive or operate machinery. Tolerance with prolonged use. Broken or eczematous skin (topical use). Pregnancy and lactation. Elderly. Children <6 yr. Dependence.
|
CNS depression e.g. drowsiness to deep sleep, lassitude, dizziness and incoordination. Headache, psychomotor impairment, dry mouth, thickening of mucous secretions, blurred vision, difficult or painful urination, constipation and increased gastric reflux. Occasionally, GI disturbances, palpitations and arrhythmias. Rashes and hypersensitivity reactions. Blood dyscrasias (rare). Convulsions, sweating, myalgia, paraesthesias, extrapyramidal effects, tremor, sleep disturbances, tinnitus, hypotension and hair loss.
|
|
|
Dry mouth, blurred vision, tachycardia, urinary retention, drowsiness, dizziness, inco-ordination, ataxia, weakness, hyperexcitability, disorientation, impaired judgement, hallucinations, hyperkinesia, extrapyramidal motor disturbances, convulsions, hyperpyrexia and respiratory depression. Gastric lavage followed by supportive measures for respiration and circulation.
|
Enhanced sedative effects of alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives, antipsychotics. Additive antimuscarinic actions with other antimuscarinic drugs and some antidepressants (TCAs and MAOIs). May mask ototoxicity symptoms caused by aminoglycoside antibiotics.
|
Description: Cyclizine is a sedative antihistamine with antimuscarinic activity.
Onset: Within 2 hr upon GI absorption.
Duration: Approximately 4 hr.
Pharmacokinetics:
Absorption: Absorbed from the GI tract.
Metabolism: Hepatically metabolised to relatively inactive metabolite.
Excretion: Plasma elimination half-lives of 20 hr.
|
|
|
Sign Out
